Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial

Diabetes mellitus is an independent risk factor for atrial fibrillation or atrial flutter (atrial arrythmia, AA). Additionally, some diabetes medications may influence AA incidence. The aim of this post hoc analysis was to assess the occurrence of AA during the study period in patients with type 2 diabetes treated with once weekly subcutaneous dulaglutide vs… Continue reading Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial

FGF1 and insulin control lipolysis by convergent pathways

Highlights•FGF1-FGFR1 signaling suppresses adipose lipolysis to curb hepatic glucose production•FGF1 suppresses lipolysis by inhibiting cAMP/PKA axis via PDE4D-S44 phosphorylation•Overexpression of PDE4D in the adipose tissue of diabetic mice corrects hyperglycemia•FGF1/PDE4D antilipolytic pathway is responsive to fed/fast states SummaryInexorable increases in insulin resistance, lipolysis, and hepatic glucose production (HGP) are hallmarks of type 2 diabetes. Previously,… Continue reading FGF1 and insulin control lipolysis by convergent pathways

Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians

Type 2 Diabetes is a metabolic disorder characterized by hyperglycemia that causes numerous complications with significant long-term morbidity and mortality. The disorder is primarily due to insulin resistance particularly in liver, skeletal muscle, and adipose tissue. In this review, we detail the hormonal mechanisms leading to the development of diabetes and discuss whether intermittent fasting… Continue reading Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians

Cytokine signature for predicting new-onset prediabetes after acute pancreatitis: A prospective longitudinal cohort study

Highlights•Interleukin-1β at baseline predicts new-onset prediabetes after acute pancreatitis. •Interferon γ at baseline predicts new-onset prediabetes after pancreatitis. •Changes in adaptive immunity may underlie glucose derangements after pancreatitis. AbstractBackground/purposeAcute inflammation of the pancreas often leads to metabolic sequelae, the most common of which is new-onset prediabetes (and, ultimately, diabetes). However, there is a lack of… Continue reading Cytokine signature for predicting new-onset prediabetes after acute pancreatitis: A prospective longitudinal cohort study

The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway

•Serum CCL-2 levels are lower in individuals with islet autoantibodies and type 1 diabetes compared to controls. •The 3p21.31 genetic locus is associated with type 1 diabetes. •Serum CCL-2 levels are associated with the 3p21.31 genetic locus. •The 3p21.31 genetic locus is associated with gene expression of the CCL-2 receptor, CCR2. AbstractMultiple cross-sectional and longitudinal… Continue reading The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway

Downregulation of Erythrocyte miR-210 Induces #Endothelial Dysfunction in Type 2 #Diabetes

Red blood cells (RBCs) act as mediators of vascular injury in type 2 diabetes mellitus (T2DM). miR-210 plays a protective role in cardiovascular homeostasis and is decreased in whole blood of T2DM mice. We hypothesized that downregulation of RBC miR-210 induces endothelial dysfunction in T2DM. RBCs were co-incubated with arteries and endothelial cells ex vivo… Continue reading Downregulation of Erythrocyte miR-210 Induces #Endothelial Dysfunction in Type 2 #Diabetes

Epidemiology of type 2 #diabetes remission in Scotland in 2019: A cross-sectional population-based study

Clinical pathways are changing to incorporate support and appropriate follow-up for people to achieve remission of type 2 diabetes, but there is limited understanding of the prevalence of remission in current practice or patient characteristics associated with remission. Methods and findingsWe carried out a cross-sectional study estimating the prevalence of remission of type 2 diabetes… Continue reading Epidemiology of type 2 #diabetes remission in Scotland in 2019: A cross-sectional population-based study

#GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize #glycemia in diabetic mice

Skeletal muscle insulin resistance is a main defect in type 2 diabetes (T2D), which is associated with impaired function and content of glucose transporter type 4 (GLUT4). GLUT4 overexpression in skeletal muscle tissue can improve glucose homeostasis. Therefore, we created an engineered muscle construct (EMC) composed of GLUT4-overexpressing (OEG4) cells. The ability of the engineered… Continue reading #GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize #glycemia in diabetic mice

Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 #Diabetes: Results from the Longitudinal Global DISCOVER Study

In a global prospective study of patients with relatively early-stage diabetes, microvascular and macrovascular complications were common and were associated with increased risk of subsequent hospitalization and death. •The strongest predictor of incident complications was the known atherosclerosis or heart failure at enrollment. •Poor glucose control and smoking were also associated with increased risk of… Continue reading Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 #Diabetes: Results from the Longitudinal Global DISCOVER Study